Aktienanalyse zu Inventiva SA (IVA)IVAInventiva SA

Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology. It operates in the Healthcare sector.

Inventiva SA (IVA) is a good buy right now, with a current price of $2.94 and a strong analyst price target of $21 from Canaccord, suggesting a potential upside of 613%. The RSI is currently at 34, indicating that the stock is oversold, which may present a buying opportunity. However, the main risk is the negative earnings per share of -0.25, reflecting ongoing losses, which investors should monitor closely.